-
Icotrokinra hydrochloride
API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status Icotrokinra hydrochloride 3049491-48-4 [Indication]
Moderate-to-severe plaque psoriasis: For the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older weighing at least 40 kg who are candidates for systemic therapy or phototherapy.
-
Iptacopan
API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status Iptacopan Hydrochloride 1646321-63-2 Feb, 2027 Jul.14, 2034 estimated PV Completion – Dec, 2026 Iptacopan Hydrochloride Monohydrate 2447007-60-3 Feb, 2027 May, 2041 estimated PV Completion – Dec, 2026 [Indication]
1. Paroxysmal nocturnal hemoglobinuria (PNH)：For the treatment of PNH in adult patients.
2. C3 glomerulopathy (C3G)：For the treatment of C3G in adult patients to reduce proteinuria.
3. Immunoglobulin A nephropathy (IgAN)：For the treatment of primary IgAN in adult patients with rapid progression risk to reduce proteinuria levels.